Cosentyx Patent Expiry Dates
Cosentyx (secukinumab), made by Novartis, has multiple patents listed in the FDA's Orange Book. The primary composition-of-matter patent (US 7,807,155) expires in 2025, but key formulation and method-of-use patents extend protection into the 2030s. The latest-expiring patent (US 9,346,011 for a specific injection formulation) runs until January 2033.[1][2]
When Can Generics Enter the Market?
No generics are approved or expected before 2033 due to these layered patents. Novartis has faced Paragraph IV challenges from companies like Alvotech and Formycon, but settlements delay launches. For instance, Alvotech's biosimilar AVT04 gained FDA approval in June 2024 but can't launch until 2028 at the earliest under a settlement, with full U.S. entry tied to patent resolutions.[3][4] True generic entry likely follows biosimilar launches, post-2033.
Biosimilars vs. Generics: What's Coming First?
Cosentyx is a biologic, so interchangeable biosimilars—not small-molecule generics—will arrive first. Yes Biosimilars' low-concentration version was FDA-approved in April 2024, but U.S. launch is blocked until at least 2031 per patent litigation outcomes.[5] At least nine biosimilars are in development globally, with European launches possible as early as 2025 (e.g., Nippon Shinyaku in Japan).[6]
| Company/Product | Status | Earliest U.S. Launch |
|-----------------|--------|----------------------|
| Alvotech (AVT04) | Approved June 2024 | 2028 (settled) |
| Yes Biosimilars (low/high concentration) | Approved April 2024 | 2031+ (litigation) |
| Formycon (FYB202) | Phase 3 complete | 2029+ (challenged) |
Why the Delays Keep Piling Up?
Secondary patents on devices, dosing, and stability create "patent thickets." Ongoing lawsuits, like Novartis vs. Alvotech, have upheld most claims, pushing back competition. If challengers win appeals, earlier entry could happen, but experts predict 2030+ for meaningful price drops.[2][7]
International Availability Timelines
- Europe: Biosimilars expected 2025–2026 after EMA approvals.
- Japan: Nippon Shinyaku's version launches 2025.
- Canada/Australia: Similar to U.S., delayed by patents until late 2020s.[6]
Impact on Pricing and Access
Biosimilars could cut costs 20–40%, based on patterns with Humira and Stelara. Patients on Cosentyx (list price ~$6,000/month) may see savings post-launch, though payer negotiations will influence real-world prices.[8]
[1]: FDA Orange Book for Cosentyx
[2]: DrugPatentWatch.com - Cosentyx Patents
[3]: Novartis-Alvotech Settlement (2024)
[4]: FDA Approval AVT04
[5]: Yes Biosimilars Approval
[6]: IQVIA Biosimilar Pipeline Report (2024)
[7]: USPTO Patent Litigation Tracker
[8]: Cosentyx Pricing - GoodRx